Artiva Biotherapeutics, Merck-partnered biotech, raised $120M to advance a pipeline of allogeneic natural killer (NK) cell therapies
DTx Pharma, rare disease treatment, $100M Series B with RA Capital, Access Biotechnology, Cormorant, Janus Henderson, Logos Capital
Truvian Sciences, blood testing tech, $105M Series C with 7wire Ventures, Wittingtong Ventures, TYH Ventures, GreatPoint Ventures
ShieldAI, defense drone tech, $90M Series C with Point72, Silicon Valley Bank
Pipeline Therapeutics, neurological disease therapies, $80M Series C with Sectoral Asset Management, Versant Ventures, Franklin Templeton
Vividion Therapeutics, novel drug discovery, $80M Series C with Alexandria Ventures, SoftBank, Logos Capital, Boxer Capital
Workiz, field service software, $13M Series B with Aleph, New Era Capital, Magenta Ventures
SpineZone, orthopedic therapy, $12M Series A with Polaris, Providence Ventures, Martin Ventures
Aptera, electric vehicle maker, $4M Series A
Micronoma, cancer detection, $3.5M with Seerave Foundation, SymBiosis
Spinogenix, neurodegenerative therapeutics, $1.5M Series Seed
JackRabbit Mobility, electric bikes, $500k